ANGN Stock Overview
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases.
Angion Biomedica Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.24|
|52 Week High||US$16.04|
|52 Week Low||US$1.08|
|1 Month Change||-19.48%|
|3 Month Change||-39.81%|
|1 Year Change||-91.84%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-92.71%|
Recent News & Updates
We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Angion Biomedica: Selling At Cash Value
Angion Biomedica Corp was the fifth worst IPO of 2021, down over 80% as its lead candidate failed one Phase 3 and two Phase 2 trials. The company recently announced a pivot to its other clinical asset – a potential therapy for fibrotic diseases of the kidney and lungs. Trading at a discount to cash but with no meaningful catalysts in 2022, the recent insider buying in Angion at least merited a deeper dive. A full investment analysis follows in the paragraphs below.
|ANGN||US Pharmaceuticals||US Market|
Return vs Industry: ANGN underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: ANGN underperformed the US Market which returned -12.9% over the past year.
|ANGN Average Weekly Movement||16.3%|
|Pharmaceuticals Industry Average Movement||11.9%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ANGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ANGN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program.
Angion Biomedica Fundamentals Summary
|ANGN fundamental statistics|
Is ANGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANGN income statement (TTM)|
|Cost of Revenue||US$43.30m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.07|
|Net Profit Margin||-108.57%|
How did ANGN perform over the long term?See historical performance and comparison
Is Angion Biomedica undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ANGN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ANGN's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ANGN is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ANGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANGN is good value based on its PB Ratio (0.6x) compared to the US Pharmaceuticals industry average (1.8x).
How is Angion Biomedica forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ANGN's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if ANGN's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ANGN's revenue (50.8% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: ANGN's revenue (50.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANGN's Return on Equity is forecast to be high in 3 years time
How has Angion Biomedica performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANGN is currently unprofitable.
Growing Profit Margin: ANGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANGN is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.
Accelerating Growth: Unable to compare ANGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).
Return on Equity
High ROE: ANGN has a negative Return on Equity (-47.81%), as it is currently unprofitable.
How is Angion Biomedica's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ANGN's short term assets ($76.2M) exceed its short term liabilities ($10.4M).
Long Term Liabilities: ANGN's short term assets ($76.2M) exceed its long term liabilities ($3.7M).
Debt to Equity History and Analysis
Debt Level: ANGN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ANGN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ANGN has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 32.8% each year.
What is Angion Biomedica current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANGN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ANGN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jay Venkatesan (49 yo)
Dr. Jay R. Venkatesan, Ph D., M.D. MBA., serves as Chairman of Angion Biomedica Corp. since January 2022 and also serves as its President since January 2019 and has been its Chief Executive Officer & Direc...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD2.54M) is above average for companies of similar size in the US market ($USD770.21K).
Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.
Experienced Management: ANGN's management team is considered experienced (2.6 years average tenure).
Experienced Board: ANGN's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Angion Biomedica Corp.'s employee growth, exchange listings and data sources
- Name: Angion Biomedica Corp.
- Ticker: ANGN
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$37.149m
- Shares outstanding: 29.96m
- Website: https://www.angion.com
Number of Employees
- Angion Biomedica Corp.
- 51 Charles Lindbergh Boulevard
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.